Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

http://www.wikidata.org/entity/Q30412800

about

Vaccines for preventing influenza in healthy adults Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines Modeling Influenza Virus Infection: A Roadmap for Influenza Research Inﬂuenza and Memory T Cells: How to Awake the Force Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review Universal influenza virus vaccines and therapeutic antibodies.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Development of universal influenza vaccines based on influenza virus M and NP genes.Universal influenza vaccines, a dream to be realized soon.Advances in influenza vaccination.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.Advances in the development of universal influenza vaccines.The prospects and challenges of universal vaccines for influenza Fast vaccine design and development based on correlates of protection (COPs).Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production Development of a universal CTL-based vaccine for influenza.Adjuvanted influenza vaccines.Development of cross-protective influenza a vaccines based on cellular responses.Influenza infection in human host: challenges in making a better influenza vaccine.Immune responses to highly conserved influenza A virus matrix 1 peptides.[Vaccinations from the pulmonologist's point of view].The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?Influenza vaccines and immunopathology Adjuvanted influenza vaccines

P2860

Q24197955-3B07DE2F-498D-4EA0-A0E9-44E8C174BBFD Q26744622-B8F2600F-0062-4384-84F6-8C37BA1BF45D Q26782421-D6FF15E2-3B17-4BDB-9221-71D954FB927A Q28070255-C6BE74E1-3804-44FF-83C2-2D1124498F61 Q28084805-C435C832-07A3-4E09-8B39-CC6CABAA0938 Q30151337-16FBFFB5-4193-46B9-B84F-C216C7CF45D4 Q30352329-9484B2C3-FD86-473E-B51C-80EB95FA8E77 Q30355116-90DB9ED5-1AA7-4134-9345-0EE07F28115B Q30361950-8BF763E7-49C9-4E85-8CB6-414B4AF92578 Q30364315-9ACD57A2-57A1-4087-AFBC-F3BDC3D68ACA Q30371303-DA7B2567-0D5E-4EFD-80A6-3ED59ED0F723 Q30372274-E7697610-EC8A-4AFE-865A-F44538FBA949 Q30387031-B58E7E83-C8E4-441F-8C41-37F830882B9C Q30399951-C7F49A3E-8CFB-44F4-BA00-B7B109B484CD Q30421502-63FB2CDE-63BD-4E90-B3BB-3D800E037BE9 Q30430703-E3416522-6722-4604-9BD1-8505FB66EEC9 Q34291098-BB450152-FF97-4D82-9E34-4A0BA89280C5 Q34650849-4C38F8A3-D7B0-4012-A4E3-408876966F83 Q35656657-C0F8D37D-45C8-4345-8C24-E3562A7B5BF4 Q37134971-25D9727E-D079-4783-AB58-5931EE1D507B Q38075677-13AB4375-E20B-4D58-AAFD-3E1D8C9AB887 Q38140045-043CCB84-DD0C-47F6-861C-3B2806756E3B Q38510148-6B93F615-E94D-40EE-92DC-85569527D102 Q38737075-C86632CA-A20D-4FD7-9EAA-45AAAA5FFCCB Q40233388-753CF989-B187-4E7F-AA4F-6C6DC549AD07 Q41172374-5E4AC1A9-7114-435C-ACAB-5DEBC48C8BDD Q47564262-C483A24C-F074-454E-A2CA-72D346EBBE29 Q56774426-D765E395-3677-43B8-9A30-EA5FCC99039F Q57094841-84AB8FAC-38A0-46EB-A57A-EBAD4AD94061

P2860

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

http://www.wikidata.org/entity/Q30412800

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

@ast

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

@en

type

label

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

@ast

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

@en

prefLabel

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

@ast

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

@en

P1433

Q30412800-E560A249-1914-4CCE-87B3-A20B7A7C321B

P1476

Q30412800-DEE04771-C72B-4E6D-B1C7-856F0537FE35

P2093

Q30412800-15A96AD1-BD6D-4373-8CCD-E631E43A9A65

Q30412800-23286F2C-918F-469C-975E-762015C3AF9E

Q30412800-519D5A0C-F5B3-48A7-8E60-010657667003

Q30412800-5C3F4980-EDD5-4D5E-8B59-2ED0F66B895F

Q30412800-7F664368-8905-463B-AA0D-6C53D6EF46C2

Q30412800-9EA44443-6A0D-413C-9287-6CCECAA2CC05

Q30412800-DB220BF2-8BA6-46A8-92CC-3A8F2DBC8BDB

P2860

Q30412800-0C7CED90-0EC5-49DC-93A8-1B8C0E94F5CA

Q30412800-14699D27-5349-47CD-8C8D-D0015707C07A

Q30412800-150950B7-F8D5-4025-A28F-F762050CCDEB

Q30412800-160E3E12-2AAC-4E84-8D30-7B45CF9F9270

Q30412800-26DE3834-262E-46DD-B052-1C8F503D4DE3

Q30412800-3360B1A6-22EB-42D6-8D5C-6B0FC53CB503

Q30412800-36D479DF-D237-4DBE-9090-0CCD4A66AE8E

Q30412800-3F8F84B2-6560-44A0-924A-53D5F85E7D40

Q30412800-69F71FBB-3009-492B-8B00-979EE6148ACD

Q30412800-7826D09C-9CFF-4457-9163-42D4BEA84E00

P2888

Q30412800-B013FA22-1DD6-4527-B447-A9F71ED4A7A7

P304

Q30412800-5F656F75-8EBE-48DA-8995-F901FFF15616

P31

Q30412800-AD267CD9-72A2-44F4-9196-3A25D2596600

P356

Q30412800-AAD30E8D-8755-4285-B6C2-C7548695C7A3

P433

Q30412800-CD6E080D-68BA-478A-B391-339F5CC28923

P478

Q30412800-8A0C3002-83DF-4B2C-BDB5-46B9FD720F08

P577

Q30412800-71355202-4CAC-497F-875C-3773113D7529

P5875

Q30412800-479AA01E-2D38-4B90-8B2B-9DDEDCC015A6

P6179

Q30412800-A1FF63F9-0EAE-47B0-85D1-1160CD29C235

P698

Q30412800-7CFB2D33-DEC4-47B0-B6CE-0AB78996D26E

P356

S10875-011-9632-5

P1433

Journal of Clinical Immunology

P1476

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

@en

P2093

Dimitry Shaikevich

http://www.w3.org/2001/XMLSchema#string

Efrat Kate-Ilovitz

http://www.w3.org/2001/XMLSchema#string

Inna Volokhov

http://www.w3.org/2001/XMLSchema#string

Jacob Atsmon

http://www.w3.org/2001/XMLSchema#string

Kirsten Y Haim

http://www.w3.org/2001/XMLSchema#string

Tamar Ben-Yedidia

http://www.w3.org/2001/XMLSchema#string

Yossi Singer

http://www.w3.org/2001/XMLSchema#string

P2860

Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.

New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.

Peptide vaccines against hepatitis B virus: from animal model to human studies.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Antibody response to influenza vaccination in the elderly: a quantitative review.

Current status of short synthetic peptides as vaccines.

Viral peptide immunogens: current challenges and opportunities.

Nanotechnology in vaccine delivery.

Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus.

Design of peptide and polypeptide vaccines.

P2888

s10875-011-9632-5

P304

595-603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10875-011-9632-5

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221817344

http://www.w3.org/2001/XMLSchema#string

P6179

1048414733

http://www.w3.org/2001/XMLSchema#string

P698

22318394

http://www.w3.org/2001/XMLSchema#string